Product Description
MediciNova is developing Ibudilast as a treatment for drug addiction, progressive multiple sclerosis, and pain. (Sourced from: https://medicinova.com/clinical-development/core/mn-166/)
Mechanisms of Action: PDE4 Inhibitor, TLR4 Antagonist, LT Antagonist, MIF Inhibitor, NOS Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Korea
Approved Indications: None
Known Adverse Events: None
Company: MediciNova
Company Location: LA JOLLA CA 92037
Company CEO: Yuichi Iwaki
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
- Clinical Outcomes Expected - MediciNova announced they will present P2 Amyotrophic Lateral Sclerosis results on 2025-12-05 for Ibudilast
- Medicinova announces a $30 million SEPA with Yorkville Advisors to advance R&D programs without issuing warrants.
- Clinical Outcomes Reported - MediciNova presented P2 Amyotrophic Lateral Sclerosis results on 2024-12-06 for Ibudilast
Highest Development Phases
Phase 3: Amyotrophic Lateral Sclerosis
Phase 2: Alcoholism|Glioblastoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| MN-166-GBM-1201 | P2 |
Completed |
Glioblastoma |
2023-08-07 |
29% |
2025-05-22 |
|
| R01AA026190 | P2 |
Completed |
Alcoholism |
2023-04-19 |
49% |
2023-07-14 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| COMBAT-ALS | P3 |
Active, not recruiting |
Amyotrophic Lateral Sclerosis |
2025-12-01 |
50% |
2025-09-17 |